PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
12911625-8	2003	4-Methylpyrazole selectively inhibited methamphetamine formation, suggesting the involvement of CYP2E1.	Fomepizole	0-16	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	96-102
12948850-8	2003	This inhibition was largely due to ethanol metabolism, as 4-methylpyrazole, an ethanol metabolism inhibitor, restored IFNgamma-mediated STAT1 phosphorylation in ethanol-treated cells.	Fomepizole	58-74	interferon gamma	Homo sapiens	118-126
12948850-8	2003	This inhibition was largely due to ethanol metabolism, as 4-methylpyrazole, an ethanol metabolism inhibitor, restored IFNgamma-mediated STAT1 phosphorylation in ethanol-treated cells.	Fomepizole	58-74	signal transducer and activator of transcription 1	Homo sapiens	136-141
12499113-10	2003	The ADH inhibitor 4-methyl pyrazole (4-MP) reduced ethanol oxidation in the skin and liver in a concentration dependent manner: activity was reduced to approximately 30-40% and approximately 2-10% of the control activity, in the skin and liver, respectively, using 1 mM 4-MP.	Fomepizole	18-35	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	4-7
12499113-10	2003	The ADH inhibitor 4-methyl pyrazole (4-MP) reduced ethanol oxidation in the skin and liver in a concentration dependent manner: activity was reduced to approximately 30-40% and approximately 2-10% of the control activity, in the skin and liver, respectively, using 1 mM 4-MP.	Fomepizole	37-41	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	4-7
12499113-10	2003	The ADH inhibitor 4-methyl pyrazole (4-MP) reduced ethanol oxidation in the skin and liver in a concentration dependent manner: activity was reduced to approximately 30-40% and approximately 2-10% of the control activity, in the skin and liver, respectively, using 1 mM 4-MP.	Fomepizole	270-274	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	4-7
15052735-3	2003	The aim of this investigation was to check the influence of some effective inhibitors of ADH and MEOS: 4-methylpyrazole, cimetidine, EDTA and 1,10-phenantroline on the activity of catalase with methanol as a substrate and the comparison with 3-amino-1,2,4-triasole.	Fomepizole	103-119	aldo-keto reductase family 1 member A1	Rattus norvegicus	89-92
12584152-4	2003	The high affinity process was catalyzed by CYP2E1, as clearly indicated by kinetic studies, correlation with chlorzoxazone 6-hydroxylation (r = 0.837; p < 0.001), and inhibition by monoclonal antihuman CYP2E1 and 4-methylpyrazole.	Fomepizole	216-232	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	43-49
12584152-4	2003	The high affinity process was catalyzed by CYP2E1, as clearly indicated by kinetic studies, correlation with chlorzoxazone 6-hydroxylation (r = 0.837; p < 0.001), and inhibition by monoclonal antihuman CYP2E1 and 4-methylpyrazole.	Fomepizole	216-232	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	205-211
15052735-3	2003	The aim of this investigation was to check the influence of some effective inhibitors of ADH and MEOS: 4-methylpyrazole, cimetidine, EDTA and 1,10-phenantroline on the activity of catalase with methanol as a substrate and the comparison with 3-amino-1,2,4-triasole.	Fomepizole	103-119	catalase	Rattus norvegicus	180-188
15052735-9	2003	4-Methylpyrazole, EDTA, 1,10-phenantroline and aminotriasole are catalase competitive inhibitors and cimetidine is non-competitive inhibitor.	Fomepizole	0-16	catalase	Rattus norvegicus	65-73
16001315-9	2001	The company"s marketing partner in Canada, Paladin Labs had launched fomepizole by January 2001 [396953].	Fomepizole	69-79	phosphatase domain containing paladin 1	Homo sapiens	43-50
12420748-8	2002	Concerning NADPH-dependent modification of CYP2E1 protein, all of the tested CYP2E1 binders, except glycerol, prevented this process with a different potency (isoniazid > 4-methylpyrazole = imidazole = pyridine 3 >> acetone > ethanol).	Fomepizole	174-190	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	77-83
12074936-0	2002	Pretreatment of CD-1 mice with 4-methylpyrazole blocks toxicity from the gamma-hydroxybutyrate precursor, 1,4-butanediol.	Fomepizole	31-47	CD1 antigen complex	Mus musculus	16-20
12074936-7	2002	Pretreatment with 4-MP significantly decreased the toxicity of 1,4-BD in CD-1 mice, presumably by inhibiting its ADH biotransformation to GHB.	Fomepizole	18-22	CD1 antigen complex	Mus musculus	73-77
11893554-8	2002	Pretreatment with the ADH inhibitor 4-methylpyrazole (4-MP) or the aldehyde dehydrogenase inhibitor cyanamide prevented or augmented the ethanol-induced inhibition, respectively, in the ADH but not the FVB group.	Fomepizole	36-52	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	22-25
11893554-8	2002	Pretreatment with the ADH inhibitor 4-methylpyrazole (4-MP) or the aldehyde dehydrogenase inhibitor cyanamide prevented or augmented the ethanol-induced inhibition, respectively, in the ADH but not the FVB group.	Fomepizole	36-52	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	186-189
11893554-8	2002	Pretreatment with the ADH inhibitor 4-methylpyrazole (4-MP) or the aldehyde dehydrogenase inhibitor cyanamide prevented or augmented the ethanol-induced inhibition, respectively, in the ADH but not the FVB group.	Fomepizole	54-58	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	22-25
11893554-8	2002	Pretreatment with the ADH inhibitor 4-methylpyrazole (4-MP) or the aldehyde dehydrogenase inhibitor cyanamide prevented or augmented the ethanol-induced inhibition, respectively, in the ADH but not the FVB group.	Fomepizole	54-58	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	186-189
12053840-3	2002	The use of 4-methylpyrazole, an inhibitor of alcohol dehydrogenase, is a new and effective treatment for patients exposed to toxic alcohols.	Fomepizole	11-27	aldo-keto reductase family 1 member A1	Homo sapiens	45-66
11410717-0	2001	4-Methylpyrazole decreases salivary acetaldehyde levels in aldh2-deficient subjects but not in subjects with normal aldh2.	Fomepizole	0-16	aldehyde dehydrogenase 2 family member	Homo sapiens	59-64
11410717-13	2001	CONCLUSIONS: A single dose of 4-MP before ethanol ingestion reduces ethanol elimination rate, the flushing reaction, and both blood and salivary acetaldehyde levels in ALDH2-deficient subjects but not in subjects with the normal ALDH2 genotype.	Fomepizole	30-34	aldehyde dehydrogenase 2 family member	Homo sapiens	168-173
11397396-6	2001	The oxidation of CD was inhibited by 4-methyl pyrazole, an inhibitor of CYP 2E1.	Fomepizole	37-54	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	72-79
12399160-10	2002	Metabolism and residue formation were blocked by the ADH inhibitor 4-methyl pyrazole (4-MP).	Fomepizole	67-84	aldo-keto reductase family 1 member A1	Homo sapiens	53-56
12399160-10	2002	Metabolism and residue formation were blocked by the ADH inhibitor 4-methyl pyrazole (4-MP).	Fomepizole	86-90	aldo-keto reductase family 1 member A1	Homo sapiens	53-56
12386121-8	2002	The chemical inhibitors ketoconazole (CYP3A) and 7-EFC (CYP2B6) inhibited both 2- and 3-hydroxycarbamazepine formation whereas 4-methylpyrazole (CYP2E1) markedly decreased 2-hydroxycarbamazepine formation.	Fomepizole	127-143	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-43
12386121-8	2002	The chemical inhibitors ketoconazole (CYP3A) and 7-EFC (CYP2B6) inhibited both 2- and 3-hydroxycarbamazepine formation whereas 4-methylpyrazole (CYP2E1) markedly decreased 2-hydroxycarbamazepine formation.	Fomepizole	127-143	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	145-151
12184789-7	2002	Both cytotoxicity and glutathione loss were abolished by the alcohol dehydrogenase inhibitor 4-methylpyrazole, indicating an oxidation product mediated these effects.	Fomepizole	93-109	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	61-82
11893554-9	2002	The ADH transgene also substantiated the ethanol-induced inhibition of maximal velocity of shortening/relengthening and unmasked an ethanol-induced prolongation of the duration of shortening/relengthening, which was abolished by 4-MP.	Fomepizole	229-233	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	4-7
11434452-11	2001	Like ethanol, fomepizole inhibits alcohol dehydrogenase; however it does so without producing serious adverse effects.	Fomepizole	14-24	aldo-keto reductase family 1 member A1	Homo sapiens	34-55
11181498-10	2001	The CYP2E1 inhibitor, 4-methylpyrazole, inhibited the formation of 6-hydroxychlorzoxazone in brain, kidney, and liver microsomes.	Fomepizole	22-38	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	4-10
11172179-3	2001	We performed a multicenter study to evaluate fomepizole, an inhibitor of alcohol dehydrogenase, in the treatment of patients with methanol poisoning.	Fomepizole	45-55	aldo-keto reductase family 1 member A1	Homo sapiens	73-94
11128434-4	2000	Fomepizole, an inhibitor of alcohol dehydrogenase, slows the metabolism of these substances and is now approved by the US Food and Drug Administration for use in ethylene glycol intoxication.	Fomepizole	0-10	aldo-keto reductase family 1 member A1	Homo sapiens	28-49
11762672-6	2001	This case report confirms highly efficient inhibition of alcohol dehydrogenase by fomepizole, as well as demonstrate the safety of fomepizole in a patient already exhibiting end-organ retinal toxicity.	Fomepizole	82-92	aldo-keto reductase family 1 member A1	Homo sapiens	57-78
11762672-7	2001	The potential for fomepizole to inhibit retinol dehydrogenase, an isoenzyme of alcohol dehydrogenase essential to vision, did not appear to be clinically significant in this symptomatic methanol-poisoned patient.	Fomepizole	18-28	alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide	Homo sapiens	40-61
11762672-7	2001	The potential for fomepizole to inhibit retinol dehydrogenase, an isoenzyme of alcohol dehydrogenase essential to vision, did not appear to be clinically significant in this symptomatic methanol-poisoned patient.	Fomepizole	18-28	aldo-keto reductase family 1 member A1	Homo sapiens	79-100
11099610-4	2000	A new alcohol dehydrogenase inhibitor, fomepizole (4-methylpyrazole), was approved in 1997 for patients at least 12 years old with suspected or confirmed EG poisoning.	Fomepizole	39-49	aldo-keto reductase family 1 member A1	Homo sapiens	6-27
11099610-4	2000	A new alcohol dehydrogenase inhibitor, fomepizole (4-methylpyrazole), was approved in 1997 for patients at least 12 years old with suspected or confirmed EG poisoning.	Fomepizole	51-67	aldo-keto reductase family 1 member A1	Homo sapiens	6-27
10606766-6	2000	We propose that ADHII represents the previously observed additional retinoid oxidation activity of rat liver cytosol which occurred in the presence of either ethanol or 4-methylpyrazole.	Fomepizole	169-185	alcohol dehydrogenase 4 (class II), pi polypeptide	Rattus norvegicus	16-21
10734030-12	2000	Inhibition of ADH by 4MP prevented ethanol-induced cell activation.	Fomepizole	21-24	aldo-keto reductase family 1 member A1	Rattus norvegicus	14-17
10644046-6	2000	4-Methylpyrazole, a potent inhibitor of class I ADH, inhibited the 5HIAL reduction in homogenates of lung, kidney, jejunum, ileum, and colon, and caused a marked drop in 5HTOL oxidation in all tissues except stomach and spleen.	Fomepizole	0-16	aldo-keto reductase family 1 member A1	Rattus norvegicus	48-51
10793034-0	2000	Childhood diethylene glycol poisoning treated with alcohol dehydrogenase inhibitor fomepizole and hemodialysis.	Fomepizole	83-93	aldo-keto reductase family 1 member A1	Homo sapiens	51-72
10793034-6	2000	We report a case of DEG ingestion in a 17-month-old girl who was managed with activated charcoal, fomepizole (a recently available alcohol dehydrogenase inhibitor), and hemodialysis (HD).	Fomepizole	98-108	aldo-keto reductase family 1 member A1	Homo sapiens	131-152
10729359-11	2000	Moreover, the N-dealkylation pathways of deprenyl are inhibited by 4-methylpyrazole and disulfiram, two CYP2E1 inhibitors.	Fomepizole	67-83	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	104-110
10510285-7	1999	Similarly, diphenyleneiodonium chloride, which inhibits NADPH-dependent electron transfer, prevented the degradation of CYP2E1, as did 4-methylpyrazole, a ligand which increases the level of CYP2E1.	Fomepizole	135-151	2,4-dienoyl-CoA reductase 1	Homo sapiens	56-61
10510285-7	1999	Similarly, diphenyleneiodonium chloride, which inhibits NADPH-dependent electron transfer, prevented the degradation of CYP2E1, as did 4-methylpyrazole, a ligand which increases the level of CYP2E1.	Fomepizole	135-151	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	120-126
10510285-7	1999	Similarly, diphenyleneiodonium chloride, which inhibits NADPH-dependent electron transfer, prevented the degradation of CYP2E1, as did 4-methylpyrazole, a ligand which increases the level of CYP2E1.	Fomepizole	135-151	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	191-197
10029205-8	1999	The ethanol-induced apoptosis was prevented by 4-methylpyrazole, an inhibitor of ethanol oxidation by CYP2E1, and by trolox, an antioxidant that prevents lipid peroxidation.	Fomepizole	47-63	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	102-108
10101151-10	1999	Pulse-chase studies conducted 72 h after removal of Tc indicated a rapid turnover of CYP2E1 with a half-life of 3.9 h. Addition of the ligand, 4-methylpyrazole, and the suicide substrate, 1-aminobenzotrizole, decreased the degradation of CYP2E1.	Fomepizole	143-159	cytochrome P450 2E1	Oryctolagus cuniculus	85-91
9972923-5	1999	Pretreatment with 4-methylpyrazole (4-MP) to inhibit ADH did not result in increased lethality to allyl alcohol or ethanol alone, but significantly reduced the lethality of the combined treatment.	Fomepizole	18-34	aldo-keto reductase family 1 member A1	Rattus norvegicus	53-56
9972923-5	1999	Pretreatment with 4-methylpyrazole (4-MP) to inhibit ADH did not result in increased lethality to allyl alcohol or ethanol alone, but significantly reduced the lethality of the combined treatment.	Fomepizole	36-40	aldo-keto reductase family 1 member A1	Rattus norvegicus	53-56
10334873-4	1999	The synergistic mitogenic effects of ethanol and S1P were also slightly enhanced, rather than inhibited, by the alcohol dehydrogenase inhibitor 4-methylpyrazole (5 mM).	Fomepizole	144-160	sphingosine-1-phosphate receptor 1	Mus musculus	49-52
9952314-5	1999	Imidazole, pyrazole, and 4-methylpyrazole, known as inducers of the ethanol-inducible CYP2E1, displaced [3H]norharman with relative high potency.	Fomepizole	25-41	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	86-92
10029205-14	1999	The prevention of the ethanol-induced apoptosis by 4-methylpyrazole and by trolox suggests that production of a prooxidative state as a consequence of ethanol oxidation by CYP2E1 results in eventual activation of caspases such as caspases 1 and 3, which can trigger the apoptotic process.	Fomepizole	51-67	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	172-178
9736485-8	1998	The alcohol dehydrogenase-specific inhibitor 4-methylpyrazole inhibited the oxidation of thiodiglycol by the pure horse liver enzyme as well as by the enzymes in human skin and mouse liver cytosol, indicating that the activity in the tissue preparations is also alcohol dehydrogenase.	Fomepizole	45-61	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	4-25
9884161-3	1998	Selective inhibitors-4-methylpyrazole (CYP2E1), furafylline (CYP1A2), and troleandomycin (CYP3A4)-also decreased microsomal ethanol oxidation in the livers of 18 organ donors.	Fomepizole	21-37	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	39-45
9733671-7	1998	Benzylimidazole, a cytochrome P450 inhibitor, decreased the clearance of BDD (25 mg/kg) by 44%, whereas 4-methylpyrazole, an alcohol dehydrogenase and cytochrome P450 inhibitor, decreased BDD clearance by 82%.	Fomepizole	104-120	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	125-146
9848112-7	1998	Incubation of colon and liver cytosols with the ADH-3 inhibitor 4-methylpyrazole markedly (95-100% of controls) reduced ethanol oxidation in both strains.	Fomepizole	64-80	alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide	Mus musculus	48-53
9848112-8	1998	However, 4-methylpyrazole was a less effective inhibitor of benzyl alcohol oxidation in AKR/J colons, suggesting a different ADH isoform complement.	Fomepizole	9-25	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	125-128
9651397-4	1998	Carbenoxolone (IC50 = 2 microM) and 4-methylpyrazole (IC50 = 5 mM) inhibited CRAD2, but neither ethanol nor phosphatidylcholine had marked effects on its activity.	Fomepizole	36-52	retinol dehydrogenase 7	Mus musculus	77-82
10030456-2	1998	Nitrosodimethylamine labeled with 14C on both methyl groups was administered to rats and exhaled 14CO2 was collected during 2-3 h. The nitrosodimethylamine breath test was increased by inducers of CYP2E1, such as ethanol (+139%) and 4-methylpyrazole (+115%), and decreased by the inhibitor diallyl sulfide (-53%).	Fomepizole	233-249	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	197-203
10030456-4	1998	The specificity of the induction by 4-methylpyrazole and of the inhibition by diallyl sulfide for CYP2E1 was determined using the [14C]caffeine (CYP1A2), [14C]aminopyrine (CYP2C11), and [14C]erythromycin (CYP3A2) breath tests.	Fomepizole	36-52	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	172-179
9531510-4	1998	The isolated enzyme has, as well, several characteristics that are unique to alcohol dehydrogenase (ADH) class III isoenzyme: it is capable of catalysing the NAD+-dependent oxidations of octanol (insensitive to inhibition by 4-methylpyrazole), methylcrotyl alcohol (stimulated by added pentanoate) and 12-hydroxydodecanoic acid, and also the NADH/NADPH-dependent reduction of octanal.	Fomepizole	225-241	alcohol dehydrogenase 5 (class III), chi polypeptide	Rattus norvegicus	100-103
9736485-8	1998	The alcohol dehydrogenase-specific inhibitor 4-methylpyrazole inhibited the oxidation of thiodiglycol by the pure horse liver enzyme as well as by the enzymes in human skin and mouse liver cytosol, indicating that the activity in the tissue preparations is also alcohol dehydrogenase.	Fomepizole	45-61	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	262-283
9407098-4	1997	Unlike recombinant retinol dehydrogenase isozymes, recombinant CRAD was inhibited by 4-methylpyrazole, was not stimulated by ethanol, and did not require phosphatidylcholine for optimal activity.	Fomepizole	85-101	retinol dehydrogenase 16	Mus musculus	63-67
9398786-1	1997	Treatment of human methanol poisoning with the alcohol dehydrogenase inhibitor, 4-methylpyrazole (fomepizole), has not been previously described.	Fomepizole	80-96	aldo-keto reductase family 1 member A1	Homo sapiens	47-68
9438519-7	1997	Inhibitors of CYP2E1 function, such as 4-methylpyrazole, inhibited adduct formation.	Fomepizole	39-55	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	14-20
9398786-1	1997	Treatment of human methanol poisoning with the alcohol dehydrogenase inhibitor, 4-methylpyrazole (fomepizole), has not been previously described.	Fomepizole	98-108	aldo-keto reductase family 1 member A1	Homo sapiens	47-68
8961948-7	1996	Inhibition of the CCl4-induced release of calcium by 4-methylpyrazole and by anti-CYP2E1 IgG, and the requirement for NADPH, indicates that CCl4 metabolism is required for the activation of calcium release.	Fomepizole	53-69	C-C motif chemokine ligand 4	Rattus norvegicus	18-22
9363841-2	1997	The first is seen by treatment of rats with acetone, pyrazole, and 4-methyl-pyrazole, which induces CYP2E1 protein without affecting the mRNA level.	Fomepizole	67-84	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	100-106
9143349-3	1997	CYP2E1 substrates or ligands such as 4-methylpyrazole, ethanol, glycerol, and dimethyl sulfoxide protected CYP2E1 against this rapid degradation, whereas CCl4 accelerated this process.	Fomepizole	37-53	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	0-6
9143349-3	1997	CYP2E1 substrates or ligands such as 4-methylpyrazole, ethanol, glycerol, and dimethyl sulfoxide protected CYP2E1 against this rapid degradation, whereas CCl4 accelerated this process.	Fomepizole	37-53	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	107-113
9143352-7	1997	The following chemicals were classified as strong inhibitors of CYP2A6 (defined by Ki < 200 microM): clotrimazole, diethyldithiocarbamate, ellipticine, ketoconazole, 8-methoxypsoralen, 4-methylpyrazole, metyrapone, miconazole, alpha-naphthoflavone, nicotine, p-nitrophenol, and tranylcypromine.	Fomepizole	188-204	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	64-70
12223617-6	1997	The in vivo activity of alcohol dehydrogenase was inhibited 40 to 60% by 4-methylpyrazole (4-MP), a competitive inhibitor of this enzyme.	Fomepizole	73-89	alcohol dehydrogenase	Solanum lycopersicum	24-45
12223617-6	1997	The in vivo activity of alcohol dehydrogenase was inhibited 40 to 60% by 4-methylpyrazole (4-MP), a competitive inhibitor of this enzyme.	Fomepizole	91-95	alcohol dehydrogenase	Solanum lycopersicum	24-45
8961948-7	1996	Inhibition of the CCl4-induced release of calcium by 4-methylpyrazole and by anti-CYP2E1 IgG, and the requirement for NADPH, indicates that CCl4 metabolism is required for the activation of calcium release.	Fomepizole	53-69	C-C motif chemokine ligand 4	Rattus norvegicus	140-144
8831679-2	1996	Microsomes isolated from MVh2E1-9 cells catalyzed a slow degradation of the expressed CYP2E1, which was prevented by the addition of 4-methylpyrazole, a ligand which stabilizes CYP2E1.	Fomepizole	133-149	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	86-92
8971135-9	1996	This is supported by the observation that 4-methylpyrazole, a CYP2E1 inhibitor, inhibited the NADPH-dependent binding of [14C]halothane to microsomal protein.	Fomepizole	42-58	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	62-68
8863822-9	1996	Consistent with CYP2A3 being a major catalyst in microsomal metabolism of DCBN, the activities of both CYP2A3 and rat olfactory microsomes in DCBN metabolism were inhibited strongly by metyrapone and methoxsalen (ID50 < 1 microM, with DCBN at 30 microM), but only marginally by 4-methylpyrazole, an inhibitor of CYP2E1.	Fomepizole	281-297	cytochrome P450, family 2, subfamily a, polypeptide 3	Rattus norvegicus	16-22
8863822-9	1996	Consistent with CYP2A3 being a major catalyst in microsomal metabolism of DCBN, the activities of both CYP2A3 and rat olfactory microsomes in DCBN metabolism were inhibited strongly by metyrapone and methoxsalen (ID50 < 1 microM, with DCBN at 30 microM), but only marginally by 4-methylpyrazole, an inhibitor of CYP2E1.	Fomepizole	281-297	cytochrome P450, family 2, subfamily a, polypeptide 3	Rattus norvegicus	103-109
8831679-2	1996	Microsomes isolated from MVh2E1-9 cells catalyzed a slow degradation of the expressed CYP2E1, which was prevented by the addition of 4-methylpyrazole, a ligand which stabilizes CYP2E1.	Fomepizole	133-149	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	177-183
8763899-14	1996	4-Methylpyrazole, a CYP2E1 and alcohol dehydrogenase inhibitor, prevented both CE-induced hepatic and cerebral GSH depletion and paralysis.	Fomepizole	0-16	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	20-26
8763899-14	1996	4-Methylpyrazole, a CYP2E1 and alcohol dehydrogenase inhibitor, prevented both CE-induced hepatic and cerebral GSH depletion and paralysis.	Fomepizole	0-16	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	31-52
8620335-6	1996	Inhibition of ethanol oxidation by 4-methylpyrazole resulted in CETP activity similar to that of the controls.	Fomepizole	35-51	cholesteryl ester transfer protein	Homo sapiens	64-68
8860965-4	1996	The 8-hydroxylation at a substrate concentration, where most of the total activity was attributed to the catalysis of the high-capacity phase, was markedly impaired by CYP2E inhibitors such as 4-methylpyrazole and aminoacetonitrile, whereas the N-demethylations were little affected by these agents.	Fomepizole	193-209	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	168-173
8771567-8	1996	Additional acetone-treated rats were given 4-methyl pyrazole, a ligand specific for CYP2E1, intraperitoneally five hours after garlic compound administration.	Fomepizole	43-60	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	84-90
8620572-6	1996	The change in CYP2E1 and CYP2C11 was confirmed by the increase and decrease in the activities inhibited by 4-methylpyrazole and cimetidine, respectively.	Fomepizole	107-123	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	14-20
8620572-6	1996	The change in CYP2E1 and CYP2C11 was confirmed by the increase and decrease in the activities inhibited by 4-methylpyrazole and cimetidine, respectively.	Fomepizole	107-123	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	25-32
8531136-9	1995	This increase was completely prevented by 4-methylpyrazole and ethanol indicating its dependence on CYP2E1.	Fomepizole	42-58	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	100-106
7499345-8	1995	Similar to microsomal RoDH and RoDH(I), RoDH(II) had higher activity with NADP rather than NAD, was stimulated by ethanol and phosphatidyl choline, was not inhibited by the medium-chain alcohol dehydrogenase inhibitor 4-methylpyrazole, but was inhibited by phenylarsine oxide and the short-chain dehydrogenase/reductase inhibitor carbenoxolone.	Fomepizole	218-234	retinol dehydrogenase 16	Rattus norvegicus	40-48
7925420-10	1994	The reaction is inhibited by pyrazole and 4-methylpyrazole, inhibitors of alcohol dehydrogenase, and by substrates of the enzyme such as ethanol and 20-hydroxy-leukotriene B4.	Fomepizole	42-58	aldo-keto reductase family 1 member A1	Rattus norvegicus	74-95
7546332-0	1995	4-Methylpyrazole, an alcohol dehydrogenase inhibitor, exacerbates alcohol-induced microencephaly during the brain growth spurt.	Fomepizole	0-16	aldo-keto reductase family 1 member A1	Rattus norvegicus	21-42
7546332-2	1995	The present study addressed this issue by using an alcohol dehydrogenase (ADH) inhibitor, 4-methylpyrazole (4-MP), that works by blocking the metabolism of alcohol to its primary metabolite acetaldehyde, thereby prolonging the actions of alcohol while minimizing the generation of acetaldehyde.	Fomepizole	90-106	aldo-keto reductase family 1 member A1	Rattus norvegicus	51-72
7546332-2	1995	The present study addressed this issue by using an alcohol dehydrogenase (ADH) inhibitor, 4-methylpyrazole (4-MP), that works by blocking the metabolism of alcohol to its primary metabolite acetaldehyde, thereby prolonging the actions of alcohol while minimizing the generation of acetaldehyde.	Fomepizole	90-106	aldo-keto reductase family 1 member A1	Rattus norvegicus	74-77
7546332-2	1995	The present study addressed this issue by using an alcohol dehydrogenase (ADH) inhibitor, 4-methylpyrazole (4-MP), that works by blocking the metabolism of alcohol to its primary metabolite acetaldehyde, thereby prolonging the actions of alcohol while minimizing the generation of acetaldehyde.	Fomepizole	108-112	aldo-keto reductase family 1 member A1	Rattus norvegicus	51-72
7604387-0	1995	Differences in teratogenic and toxic properties of alcohol dehydrogenase inhibitors pyrazole and 4-methylpyrazole in Drosophila melanogaster: I.	Fomepizole	97-113	Alcohol dehydrogenase	Drosophila melanogaster	51-72
7604387-2	1995	Pyrazole and 4-methylpyrazole (4-MP) are effective inhibitors of alcohol dehydrogenase (ADH) activity in mammals both in vivo and in vitro.	Fomepizole	13-29	Alcohol dehydrogenase	Drosophila melanogaster	65-86
7604387-2	1995	Pyrazole and 4-methylpyrazole (4-MP) are effective inhibitors of alcohol dehydrogenase (ADH) activity in mammals both in vivo and in vitro.	Fomepizole	13-29	Alcohol dehydrogenase	Drosophila melanogaster	88-91
7604387-2	1995	Pyrazole and 4-methylpyrazole (4-MP) are effective inhibitors of alcohol dehydrogenase (ADH) activity in mammals both in vivo and in vitro.	Fomepizole	31-35	Alcohol dehydrogenase	Drosophila melanogaster	65-86
7604387-2	1995	Pyrazole and 4-methylpyrazole (4-MP) are effective inhibitors of alcohol dehydrogenase (ADH) activity in mammals both in vivo and in vitro.	Fomepizole	31-35	Alcohol dehydrogenase	Drosophila melanogaster	88-91
7546332-2	1995	The present study addressed this issue by using an alcohol dehydrogenase (ADH) inhibitor, 4-methylpyrazole (4-MP), that works by blocking the metabolism of alcohol to its primary metabolite acetaldehyde, thereby prolonging the actions of alcohol while minimizing the generation of acetaldehyde.	Fomepizole	108-112	aldo-keto reductase family 1 member A1	Rattus norvegicus	74-77
7546332-8	1995	These findings indicate that 4-MP is an effective nontoxic ADH inhibitor and that microencephaly is associated with BAC levels.	Fomepizole	29-33	aldo-keto reductase family 1 member A1	Rattus norvegicus	59-62
7589226-4	1995	A similar stabilizing effect was also observed for inhibitors of CYP2E1, e.g. imidazole, 4-methylpyrazole, and isoniazid.	Fomepizole	89-105	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	65-71
7999766-7	1994	A Tyr93Phe mutant exhibits decreased kcat values for substrates in general and correlates with inhibition of alcohol dehydrogenase activity by 4-methylpyrazole, a potent inhibitor of the class I enzymes.	Fomepizole	143-159	aldo-keto reductase family 1 member A1	Homo sapiens	109-130
7943667-14	1994	Growth inhibition was blocked by the alcohol dehydrogenase inhibitor 4-methylpyrazole, suggesting that acetaldehyde and not ethanol was responsible for growth inhibition in these cells.	Fomepizole	69-85	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	37-58
8470894-9	1993	CCl4 decreased cellular viability in hepatocytes from streptozotocin- or 4MP-treated rats, and increased toxicity was found after treatment with both inducers.	Fomepizole	73-76	C-C motif chemokine ligand 4	Rattus norvegicus	0-4
8032149-10	1994	4-methylpyrazole inhibits H. pylori ADH, and suppresses its growth during culture.	Fomepizole	0-16	aldo-keto reductase family 1 member A1	Homo sapiens	36-39
8489262-1	1993	Recently, it was demonstrated that 4-methylpyrazole was not only an inhibitor of alcohol dehydrogenase but also caused competitive inhibition of fatty acyl-CoA synthetase, the enzyme which activates fatty acids (B. U. Bradford, D. T. Forman, and R. G. Thurman, 1993, Mol.	Fomepizole	35-51	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	81-102
8423764-0	1993	4-Methylpyrazole inhibits fatty acyl coenzyme synthetase and diminishes catalase-dependent alcohol metabolism: has the contribution of alcohol dehydrogenase to alcohol metabolism been previously overestimated?	Fomepizole	0-16	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	135-156
1469101-6	1992	Pretreatment of rats with isonicotinic acid hydrazide and phenobarbital to induce cytochrome P-450 enhanced the production of F2-isoprostanes after CCl4 administration eightfold and fivefold, respectively, whereas inhibition of the cytochrome P-450 system with SKF-525A and 4-methylpyrazole decreased formation of F2-isoprostanes after CCl4 by 55 and 82%, respectively.	Fomepizole	274-290	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	82-98
1616124-4	1992	Selective inhibition of class I ADH by 4-methylpyrazole further increases the specificity.	Fomepizole	39-55	aldo-keto reductase family 1 member A1	Homo sapiens	32-35
1627587-0	1992	Time course characterization of the induction of cytochrome P-450 2E1 by pyrazole and 4-methylpyrazole.	Fomepizole	86-102	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	49-69
1627587-7	1992	A single treatment with 4-methylpyrazole increased P-450 2B1/B2 levels and oxidation of pentoxyresorufin about 2- to 3-fold.	Fomepizole	24-40	immunoglobulin kappa variable 5-2	Homo sapiens	57-63
1627587-9	1992	Although significant, the induction of 2B1/B2 by 4-methylpyrazole is more than an order of magnitude less than that by phenobarbital.	Fomepizole	49-65	immunoglobulin kappa variable 5-2	Homo sapiens	39-45
1590359-4	1992	Pretreatment of hepatocytes with 100 microM 4-methylpyrazole, an inhibitor of alcohol dehydrogenase, completely blocked ethanol-induced increases in extracellular adenosine at 12.5 and 25 mM ethanol.	Fomepizole	44-60	aldo-keto reductase family 1 member A1	Rattus norvegicus	78-99
1482289-2	1992	A 96% reduction of the area under the concentration-versus-time-curve (AUC) of metabolically generated all-trans retinoic acid in maternal plasma, and an 84% decrease in the embryonic AUC were observed when mice had been pretreated with the alcohol dehydrogenase inhibitor 4-methylpyrazole.	Fomepizole	273-289	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	241-262
2394940-6	1990	Ethanol-mediated inactivation of ALAD was reduced by inhibition of alcohol dehydrogenase with 4-methylpyrazole, but ALAD activity was not decreased by incubation of undiluted cytosol with acetate or sorbitol or by addition of acetate to the assay mix.	Fomepizole	94-110	aminolevulinate dehydratase	Rattus norvegicus	33-37
1728667-8	1992	Pulmonary ADH is less sensitive to inhibition by 4-methylpyrazole than is hepatic ADH, as evidenced by a 1000-fold higher Ki.	Fomepizole	49-65	aldo-keto reductase family 1 member A1	Rattus norvegicus	10-13
2269284-6	1990	The chicken protein analyzed proves to be a class I alcohol dehydrogenase, with 74% residue identity to gamma chains of the human enzyme, a Km for ethanol of 0.5 mM and a Ki for 4-methyl pyrazole of 2.5 microM.	Fomepizole	178-195	alcohol dehydrogenase 6 (class V)	Gallus gallus	44-73
2129178-4	1990	It is referred to the therapy by means of 4-methyl pyrazol which prevents the intoxication of ethylene glycol, whereby this substance in an effective inhibitor of the alcohol dehydrogenase.	Fomepizole	42-58	aldo-keto reductase family 1 member A1	Homo sapiens	167-188
1687018-3	1991	Formaldehyde production was inhibited by substrates and ligands for cytochrome P-450 such as aniline, p-nitrophenol, pyrazole, and 4-methylpyrazole, and inhibitors such as tryptamine, cimetidine, and miconazole.	Fomepizole	131-147	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	68-84
1985938-7	1991	sigma-ADH is strongly inhibited by 4-methylpyrazole, but with a Ki (10 microM) still higher than that for a class I isoenzyme.	Fomepizole	35-51	alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide	Homo sapiens	0-9
1806149-4	1991	The SCE-inducing effect of ethanol disappears in the presence of 4-methylpyrazole (4-MP), an inhibitor of alcohol dehydrogenase (ADH).	Fomepizole	65-81	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	106-127
1806149-4	1991	The SCE-inducing effect of ethanol disappears in the presence of 4-methylpyrazole (4-MP), an inhibitor of alcohol dehydrogenase (ADH).	Fomepizole	65-81	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	129-132
1806149-4	1991	The SCE-inducing effect of ethanol disappears in the presence of 4-methylpyrazole (4-MP), an inhibitor of alcohol dehydrogenase (ADH).	Fomepizole	83-87	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	106-127
1806149-4	1991	The SCE-inducing effect of ethanol disappears in the presence of 4-methylpyrazole (4-MP), an inhibitor of alcohol dehydrogenase (ADH).	Fomepizole	83-87	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	129-132
2099148-4	1990	mu-Alcohol dehydrogenase stood out in high Km values for both ethanol (18 mM) and NAD+ (340 microM) as well as in high Ki value (320 microM) for 4-methylpyrazole, a competitive inhibitor for ethanol.	Fomepizole	145-161	aldo-keto reductase family 1 member A1	Homo sapiens	3-24
2306278-5	1990	This reaction was sensitive to inhibition by carbon monoxide and was inhibited by compounds known to be effective substrates for P-450j, e.g. aniline, ethanol, pyrazole and 4-methylpyrazole.	Fomepizole	173-189	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	129-135
34709101-4	2022	Fomepizole has proven safety in methanol and ethylene glycol poisoning and is a potent CYP2E1 and c-Jun-N-terminal Kinase (JNK) inhibitor that is effective even in the metabolic phase.	Fomepizole	0-10	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	87-93
2295642-4	1990	Both effects of butanol were blocked by an inhibitor of ADH, 4-methylpyrazole, consistent with the hypothesis that elevation of the NADH redox state by butanol inhibited H2O2 production via NAD+-requiring peroxisomal beta-oxidation, leading indirectly to diminished rates of catalase-dependent methanol uptake.	Fomepizole	61-77	alcohol dehydrogenase 1C (class I), gamma polypeptide	Rattus norvegicus	56-59
2295642-4	1990	Both effects of butanol were blocked by an inhibitor of ADH, 4-methylpyrazole, consistent with the hypothesis that elevation of the NADH redox state by butanol inhibited H2O2 production via NAD+-requiring peroxisomal beta-oxidation, leading indirectly to diminished rates of catalase-dependent methanol uptake.	Fomepizole	61-77	catalase	Rattus norvegicus	275-283
10679205-6	2000	Fasting and administration of acetone and 4-methylpyrazole increased Cyp2e1 mRNA as well as protein and activity in both obese and lean mice.	Fomepizole	42-58	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	69-75
21156189-8	2011	In cultured human or mouse HSC, production of CTGF, alpha-SMA and/or collagen was increased by ethanol treatment, an effect mimicked by acetaldehyde and blocked by 4-methylpyrazole (4-MP) or N-acetylcysteine (NAC).	Fomepizole	164-180	cellular communication network factor 2	Mus musculus	46-50
21156189-8	2011	In cultured human or mouse HSC, production of CTGF, alpha-SMA and/or collagen was increased by ethanol treatment, an effect mimicked by acetaldehyde and blocked by 4-methylpyrazole (4-MP) or N-acetylcysteine (NAC).	Fomepizole	182-186	cellular communication network factor 2	Mus musculus	46-50
21156189-8	2011	In cultured human or mouse HSC, production of CTGF, alpha-SMA and/or collagen was increased by ethanol treatment, an effect mimicked by acetaldehyde and blocked by 4-methylpyrazole (4-MP) or N-acetylcysteine (NAC).	Fomepizole	182-186	actin alpha 2, smooth muscle, aorta	Mus musculus	52-61
34709101-4	2022	Fomepizole has proven safety in methanol and ethylene glycol poisoning and is a potent CYP2E1 and c-Jun-N-terminal Kinase (JNK) inhibitor that is effective even in the metabolic phase.	Fomepizole	0-10	mitogen-activated protein kinase 8	Homo sapiens	98-121
34709101-4	2022	Fomepizole has proven safety in methanol and ethylene glycol poisoning and is a potent CYP2E1 and c-Jun-N-terminal Kinase (JNK) inhibitor that is effective even in the metabolic phase.	Fomepizole	0-10	mitogen-activated protein kinase 8	Homo sapiens	123-126
35311442-2	2022	The treatment of patients with ethylene glycol poisoning includes competitively inhibiting alcohol dehydrogenase with ethanol or fomepizole to prevent the formation of toxic metabolites, and extracorporeal treatments such as hemodialysis to remove ethylene glycol and its metabolites.	Fomepizole	129-139	aldo-keto reductase family 1 member A1	Homo sapiens	91-112
34978586-7	2022	In animal studies, fomepizole effectively prevented APAP-induced liver injury by inhibiting Cyp2E1 when treated early, and by inhibiting c-jun N-terminal kinase (JNK) and oxidant stress when treated after the metabolism phase.	Fomepizole	19-29	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	92-98
34978586-7	2022	In animal studies, fomepizole effectively prevented APAP-induced liver injury by inhibiting Cyp2E1 when treated early, and by inhibiting c-jun N-terminal kinase (JNK) and oxidant stress when treated after the metabolism phase.	Fomepizole	19-29	mitogen-activated protein kinase 8	Homo sapiens	137-160
34978586-7	2022	In animal studies, fomepizole effectively prevented APAP-induced liver injury by inhibiting Cyp2E1 when treated early, and by inhibiting c-jun N-terminal kinase (JNK) and oxidant stress when treated after the metabolism phase.	Fomepizole	19-29	mitogen-activated protein kinase 8	Homo sapiens	162-165
2910296-3	1989	Male rats were pretreated with 4-methylpyrazole, an inhibitor of liver alcohol dehydrogenase, in doses causing an 85% inhibition of the ethanol elimination.	Fomepizole	31-47	aldo-keto reductase family 1 member A1	Rattus norvegicus	71-92
2642704-7	1989	The oxidation of PEG was inhibited by the ADH inhibitor 4-methylpyrazole.	Fomepizole	56-72	aldo-keto reductase family 1 member A1	Homo sapiens	42-45
34785186-7	2022	Fomepizole"s action is mediated by inhibition of CYP2E1 to prevent oxidant stress generation, and inhibition of c-Jun N-terminal kinase (JNK) to decrease amplification of oxidant stress signaling to mitochondria.	Fomepizole	0-10	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	49-55
34785186-7	2022	Fomepizole"s action is mediated by inhibition of CYP2E1 to prevent oxidant stress generation, and inhibition of c-Jun N-terminal kinase (JNK) to decrease amplification of oxidant stress signaling to mitochondria.	Fomepizole	0-10	mitogen-activated protein kinase 8	Homo sapiens	112-135
34785186-7	2022	Fomepizole"s action is mediated by inhibition of CYP2E1 to prevent oxidant stress generation, and inhibition of c-Jun N-terminal kinase (JNK) to decrease amplification of oxidant stress signaling to mitochondria.	Fomepizole	0-10	mitogen-activated protein kinase 8	Homo sapiens	137-140
2575510-1	1989	Pyrazole is oxidized to 4-hydroxypyrazole by rat liver microsomes in a cytochrome P-450-dependent reaction and this oxidation can be increased by prior treatment of rats with pyrazole, 4-methylpyrazole, or chronic ethanol feeding.	Fomepizole	185-201	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	71-87
2907568-1	1988	The liver alcohol dehydrogenase inhibitor, 4-methylpyrazole, has been tested for its ability to change the hypnotic concentrations of phenobarbitone (phenobarbital) in rats.	Fomepizole	43-59	aldo-keto reductase family 1 member A1	Rattus norvegicus	10-31
3056073-1	1988	4-Methylpyrazole (4-MP), an inhibitor of alcohol dehydrogenase, is a possible future drug for the treatment of methanol and ethylene glycol intoxications and the severe ethanol-disulfiram reaction.	Fomepizole	0-16	aldo-keto reductase family 1 member A1	Homo sapiens	41-62
3416882-8	1988	The increase in 4-methylpyrazole-insensitive ethanol uptake by fatty acids was blocked by the catalase inhibitor, aminotriazole, indicating the involvement of catalase.	Fomepizole	16-32	catalase	Rattus norvegicus	94-102
3416882-8	1988	The increase in 4-methylpyrazole-insensitive ethanol uptake by fatty acids was blocked by the catalase inhibitor, aminotriazole, indicating the involvement of catalase.	Fomepizole	16-32	catalase	Rattus norvegicus	159-167
3056073-1	1988	4-Methylpyrazole (4-MP), an inhibitor of alcohol dehydrogenase, is a possible future drug for the treatment of methanol and ethylene glycol intoxications and the severe ethanol-disulfiram reaction.	Fomepizole	18-22	aldo-keto reductase family 1 member A1	Homo sapiens	41-62
3056077-10	1988	Hepatocytes treated with 4-methylpyrazole, an inhibitor of ADH, were partially protected from ethanol effects.	Fomepizole	25-41	aldo-keto reductase family 1 member A1	Homo sapiens	59-62
2838090-6	1988	The reaction was inhibited by pyrazole and 4-methylpyrazole, inhibitors of alcohol dehydrogenase, and by various alcohols, such as ethanol, 12-hydroxylaurate, and 20-hydroxyprostaglandin E1.	Fomepizole	43-59	aldo-keto reductase family 1 member A1	Rattus norvegicus	75-96
2888861-1	1987	The liver alcohol dehydrogenase inhibitors, pyrazole and 4-methylpyrazole, have been tested for their ability to prolong drug-induced sleep times in mice.	Fomepizole	57-73	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	10-31
3358259-6	1988	The ADH inhibitor 4-methylpyrazole (0.12 or 1.2 mmol/kg) or ethanol (43.3 mmol/kg, single dose concomitant with ME or additional ethanol 5 and 10 hr later) reduced the incidence of malformations 60-100%, depending on the dosing regimen.	Fomepizole	18-34	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	4-7
3663241-6	1987	This suggests that an increase in affinity, which may reflect the induction of an alcohol-preferring isozyme of cytochrome P-450, is responsible for the increased inhibitory effectiveness of pyrazole and 4-methylpyrazole towards ethanol oxidation by microsomes after chronic ethanol treatment.	Fomepizole	204-220	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	112-128
3663241-8	1987	This could be due to the ability of 4-methylpyrazole, compared to pyrazole, to interact with and induce several isozymes of cytochrome P-450.	Fomepizole	36-52	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	124-140
3663241-9	1987	Pyrazole and 4-methylpyrazole are often utilized to evaluate ethanol metabolism by alcohol-dehydrogenase-dependent and -independent pathways.	Fomepizole	13-29	aldo-keto reductase family 1 member A1	Rattus norvegicus	83-104
3166980-4	1988	1,10-Phenanthroline and 4-methylpyrazole competitively inhibit both alcohol dehydrogenase catalyzed ethanol and 3 beta-hydroxy-5 beta-steroid oxidation demonstrating that the catalysis of both types of substrates occurs at the same active site.	Fomepizole	24-40	aldo-keto reductase family 1 member A1	Homo sapiens	68-89
3223428-1	1988	Pyrazole and 4-methylpyrazole are potent inhibitors of liver alcohol dehydrogenase and as such have been proposed as potential antidotes to alcohol poisoning.	Fomepizole	13-29	aldo-keto reductase family 1 member A1	Rattus norvegicus	61-82
3223428-4	1988	Total cytochrome P-450 was significantly increased (p less than 0.05) 1.3 fold by treatment with 4-methylpyrazole.	Fomepizole	97-113	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	6-22
3223429-6	1988	By combination of cDNA hybridization and immunoblot analyses, three types of P450j gene expression were observed: transcriptional activation during development; post-transcriptional activation (probably via protein stabilization) by various inducers such as pyrazole, 4-methylpyrazole, acetone, and ethanol; and mRNA stabilization in diabetic and starved animals.	Fomepizole	268-284	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	77-82
3294834-7	1987	ADH+ deermice exhibited D(V/K) values of 1.87 +/- 0.06 (untreated), 1.71 +/- 0.13 (pretreated with 3-amino-1,2,4-triazole), and 1.24 +/- 0.13 (after the ADH inhibitor, 4-methylpyrazole) at 5-7 mM blood ethanol levels.	Fomepizole	168-184	alcohol dehydrogenase 1A (class I), alpha polypeptide	Homo sapiens	0-3
3610585-2	1987	These isozymes exhibited low-Km characteristics with ethanol as substrate, high isoelectric points (8.5-9.3), and sensitivity to 5 mM 4-methyl pyrazole inhibition, and were the major liver (ADH-2) and kidney (ADH-1) isozymes in the baboon.	Fomepizole	134-151	alcohol dehydrogenase 1A (class I), alpha polypeptide	Homo sapiens	190-193
3113478-5	1987	Isoniazid, dimethyl sulfoxide, pyrazole, 4-methylpyrazole, and ethanol were inducers of cytochrome P-450j in rat liver although these compounds showed different inducing potencies.	Fomepizole	41-57	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	88-105
3544915-2	1986	Five major ADH isozymes were resolved and distinguished on the basis of their isoelectric points, tissue distributions, relative activities with alcohol substrates, and sensitivities to inhibition with 4-methyl pyrazole.	Fomepizole	202-219	alcohol dehydrogenase 1A (class I), alpha polypeptide	Homo sapiens	11-14
3303039-5	1987	Mouse lung CBR exhibited optimal activity at pH 5.0; a preference for NADPH as coenzyme, although reactive with NADH at an order of magnitude higher concentration; poor activity as an ADH, but was strongly inhibited by 4-methyl pyrazole; and was inhibited by quercitin, dithiothreitol and p-OH-mercuribenzoate, but was insensitive to valproate or sorbinil.	Fomepizole	219-236	carbonyl reductase 1	Mus musculus	11-14
3782137-14	1986	In contrast to transcriptional activation during development, induction of P450j by various agents such as pyrazole, 4-methylpyrazole, and acetone might be due to post-transcriptional events.	Fomepizole	117-133	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	75-80
3530028-3	1986	Increasing the buffering capacity of the system or the addition of a metabolic inhibitor of alcohol dehydrogenase (4-methylpyrazole) returned iron uptake to control values.	Fomepizole	115-131	aldo-keto reductase family 1 member A1	Rattus norvegicus	92-113
3827819-2	1986	Pyrazole and 4-methylpyrazole, which are inhibitors of alcohol dehydrogenase, were also found to be effective inhibitors of the oxidation of ethanol by liver microsomes (microsomal fractions) in vitro.	Fomepizole	13-29	aldo-keto reductase family 1 member A1	Rattus norvegicus	55-76
3827819-8	1986	Thus the increased inhibitory effectiveness of pyrazole and 4-methylpyrazole appears to be associated with increased interactions with the cytochrome P-450 isoenzyme(s) induced by these compounds.	Fomepizole	60-76	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	139-155
3712274-2	1986	Whereas pyrazole treatment of rats (200 mg/kg b.wt./day for 2 days) resulted in an enrichment of a cytochrome P-450 isozyme with a molecular weight of about 52,000 on sodium dodecyl sulfate gels, 4-methylpyrazole treatment resulted in increased amounts of two or three P-450 isozymes, one of which appeared to be similar to the isozyme increased by pyrazole.	Fomepizole	196-212	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	99-115
3933374-0	1985	Interaction of pyrazole and 4-methylpyrazole with hepatic microsomes: effect on cytochrome P-450 content, microsomal oxidation of alcohols, and binding spectra.	Fomepizole	28-44	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	80-96
2936266-3	1985	The cutaneous reaction to primary alcohols can be totally blocked by pretreatment with 4-methylpyrazole, a potent inhibitor of alcohol dehydrogenase.	Fomepizole	87-103	aldo-keto reductase family 1 member A1	Homo sapiens	127-148
3933374-7	1985	By contrast, the 4-methylpyrazole treatment, besides increasing the oxidation of alcohols, also increased the oxidation of aminopyrine and the content of cytochrome P-450.	Fomepizole	17-33	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	154-170
4063061-1	1985	Male C57BL/6J mice offered unrestricted access to food, water and 10% ethanol, exhibited obvious intoxication when treated with the alcohol dehydrogenase inhibitor, 4-methylpyrazole (4MP) by chronic infusion.	Fomepizole	165-181	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	132-153
4063061-1	1985	Male C57BL/6J mice offered unrestricted access to food, water and 10% ethanol, exhibited obvious intoxication when treated with the alcohol dehydrogenase inhibitor, 4-methylpyrazole (4MP) by chronic infusion.	Fomepizole	183-186	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	132-153
6346914-2	1983	The ability of 4-methylpyrazole, an inhibitor of alcohol dehydrogenase, to prevent the toxic effects of ethanol on testosterone production was investigated.	Fomepizole	15-31	aldo-keto reductase family 1 member A1	Rattus norvegicus	49-70
3160372-4	1985	4-Methylpyrazole significantly reduced the ethanol oxidation in both ADH+ and ADH- hepatocytes.	Fomepizole	0-16	alcohol dehydrogenase 1A (class I), alpha polypeptide	Homo sapiens	69-72
3160372-4	1985	4-Methylpyrazole significantly reduced the ethanol oxidation in both ADH+ and ADH- hepatocytes.	Fomepizole	0-16	alcohol dehydrogenase 1A (class I), alpha polypeptide	Homo sapiens	78-81
3160372-5	1985	The reduction seen in ADH- cells can be applied to correct for the effect of 4-methylpyrazole on non-ADH pathways of ADH+ deermouse hepatocytes.	Fomepizole	77-93	alcohol dehydrogenase 1A (class I), alpha polypeptide	Homo sapiens	22-25
6370140-2	1984	Against varied concentrations of ethanol, 4-methylpyrazole is a competitive inhibitor of purified rat liver alcohol dehydrogenase (Kis = 0.11 microM, in 83 mM potassium phosphate and 40 mM KCl buffer, pH 7.3, 37 degrees C) and is competitive in rats (with Kis = 1.4 mumol/kg).	Fomepizole	42-58	aldo-keto reductase family 1 member A1	Rattus norvegicus	108-129
6353979-4	1983	4-Methylpyrazole, an alcohol dehydrogenase inhibitor, efficiently reduced blood acetaldehyde levels when injected intravenously (7 mg/kg) at the height of the reaction.	Fomepizole	0-16	aldo-keto reductase family 1 member A1	Homo sapiens	21-42
6377951-4	1984	Oral pretreatment with the alcohol dehydrogenase inhibitor, 4-methylpyrazole, reduced ethanol elimination by 15-25% and strongly suppressed acetaldehyde accumulation.	Fomepizole	60-76	aldo-keto reductase family 1 member A1	Homo sapiens	27-48
7030108-1	1981	4-methylpyrazole (4-MP), an inhibitor of alcohol dehydrogenase, rapidly abolished the accumulation of acetaldehyde following alcohol ingestion both in volunteers pretreated with the Antabuse analog calcium carbimide and in an antabuse-treated alcoholic.	Fomepizole	0-16	aldo-keto reductase family 1 member A1	Homo sapiens	41-62
6877053-2	1983	The animals continuously oxidized ethanol due to the supplementation of the diet with a low dose of 4-methylpyrazole (4-MP, an alcohol dehydrogenase inhibitor), that decreased ethanol elimination by about 20%.	Fomepizole	100-116	aldo-keto reductase family 1 member A1	Rattus norvegicus	127-148
6877053-2	1983	The animals continuously oxidized ethanol due to the supplementation of the diet with a low dose of 4-methylpyrazole (4-MP, an alcohol dehydrogenase inhibitor), that decreased ethanol elimination by about 20%.	Fomepizole	118-122	aldo-keto reductase family 1 member A1	Rattus norvegicus	127-148
6847840-10	1983	However, administration of ethanol or 4-methyl-pyrazole diminished pentane clearance, suggesting that alcohol dehydrogenase may be involved in pentane metabolism.	Fomepizole	38-55	aldo-keto reductase family 1 member A1	Rattus norvegicus	102-123
7048061-4	1982	The infusion of 4-methylpyrazole (80 microM), an inhibitor of alcohol dehydrogenase, completely abolished the fluorescence increase in both regions, indicating that the changes are entirely attributable to perturbation of cofactor levels due to alcohol dehydrogenase-dependent ethanol metabolism.	Fomepizole	16-32	aldo-keto reductase family 1 member A1	Rattus norvegicus	62-83
7048061-4	1982	The infusion of 4-methylpyrazole (80 microM), an inhibitor of alcohol dehydrogenase, completely abolished the fluorescence increase in both regions, indicating that the changes are entirely attributable to perturbation of cofactor levels due to alcohol dehydrogenase-dependent ethanol metabolism.	Fomepizole	16-32	aldo-keto reductase family 1 member A1	Rattus norvegicus	245-266
7030108-1	1981	4-methylpyrazole (4-MP), an inhibitor of alcohol dehydrogenase, rapidly abolished the accumulation of acetaldehyde following alcohol ingestion both in volunteers pretreated with the Antabuse analog calcium carbimide and in an antabuse-treated alcoholic.	Fomepizole	18-22	aldo-keto reductase family 1 member A1	Homo sapiens	41-62
7232463-5	1981	When given from the start with cyanamide, 4-MP did affect the development of the suppression, but probably by its effect in lessening the degree of brain ALDH inhibition: a high correlation (r = +0.825, p less than 0.001) was found between brain ALDH activity and ethanol consumption.	Fomepizole	42-46	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	154-158
7232463-5	1981	When given from the start with cyanamide, 4-MP did affect the development of the suppression, but probably by its effect in lessening the degree of brain ALDH inhibition: a high correlation (r = +0.825, p less than 0.001) was found between brain ALDH activity and ethanol consumption.	Fomepizole	42-46	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	246-250
7432008-4	1980	It was shown that the inhibition of ornithine decarboxylase was most likely caused by the ethanol itself because the inhibition was still apparent after treatment with 4-methylpyrazole which so retarded acetaldehyde formation that none was detectable in the wall of the stomach and in the blood and very little in the wall of small intestine.	Fomepizole	168-184	ornithine decarboxylase 1	Rattus norvegicus	36-59
228751-6	1979	Ethanol oxidation inhibited by 50% the stimulation of ornithine decarboxylase by glucagon and dexamethasone and this effect was blocked by 4-methylpyrazole, an inhibitor of alcohol dehydrogenase.	Fomepizole	139-155	ornithine decarboxylase 1	Rattus norvegicus	54-77
6989357-4	1980	Inhibition of enhanced oxygen uptake by KCN (2mM) and 4-methylpyrazole (0.8 mM) suggested the involvement of the mitochondrial respiratory chain and alcohol dehydrogenase in this phenomenon.	Fomepizole	54-70	aldo-keto reductase family 1 member A1	Rattus norvegicus	149-170
172084-0	1975	Human liver alcohol dehydrogenase--inhibition of methanol activity by pyrazole, 4-methylpyrazole, 4-hydroxymethylpyrazole and 4-carboxypyrazole.	Fomepizole	80-96	aldo-keto reductase family 1 member A1	Homo sapiens	12-33
371455-1	1979	Rats chronically fed ethanol developed liver injury only if they also received low doses of the alcohol dehydrogenase inhibitor, 4-methylpyrazole, suggesting that the consistency of the influence of ethanol and its metabolism, rather than the level of acetaldehyde or the degree of the metabolic effects, contributes to the pathogenesis of alcoholic liver damage.	Fomepizole	129-145	aldo-keto reductase family 1 member A1	Rattus norvegicus	96-117
240743-4	1975	Direct read-out techniques for pyridine nucleotides, the catalase-H2O2 complex, and cytochrome P-450 were utilized to evaluate the specificity of inhibitors of alcohol dehydrogenase (4-methylpyrazole; 4 mM) and catalase (aminotriazole; 1.0 g/kg) qualitatively in perfused rat livers.	Fomepizole	183-199	aldo-keto reductase family 1 member A1	Rattus norvegicus	160-181
240743-5	1975	4-Methylpyrazole and aminotriazole are specific inhibitors for alcohol dehydrogenase and catalase, respectively, under these conditions.	Fomepizole	0-16	aldo-keto reductase family 1 member A1	Rattus norvegicus	63-84
240743-5	1975	4-Methylpyrazole and aminotriazole are specific inhibitors for alcohol dehydrogenase and catalase, respectively, under these conditions.	Fomepizole	0-16	catalase	Rattus norvegicus	89-97
115004-1	1979	4-Methylpyrazole, in a dose producing inhibition of alcohol dehydrogenase (alcohol:NAD(+) oxidoreductase, EC 1.1.1.1), was given alone or together with ethanol (10%) as sole drinking fluid to growing rats for up to 38 weeks.	Fomepizole	0-16	aldo-keto reductase family 1 member A1	Rattus norvegicus	52-73
415870-0	1977	Ethanol-induced hypoglycaemia in man: its suppression by the alcohol dehydrogenase inhibitor 4-methylpyrazole.	Fomepizole	93-109	aldo-keto reductase family 1 member A1	Homo sapiens	61-82
415870-1	1977	Infusion of ethanol (0.6 g/kg body wt) caused marked hypoglycaemia in subjects fasted for 36 h. Previous administration of the alcohol dehydrogenase (ADH) inhibitor 4-methylpyrazole (4-MP, 7 mg/kg body wt i.v.)	Fomepizole	165-181	aldo-keto reductase family 1 member A1	Homo sapiens	127-148
33157119-2	2020	We have shown that 4-methylpyrazole (4MP, Fomepizole) protects against APAP-induced liver injury by inhibiting reactive metabolite formation through Cyp2E1, and analysis of data from APAP overdose patients indicated that kidney dysfunction strongly correlated with severe liver injury.	Fomepizole	19-35	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	149-155
33157119-2	2020	We have shown that 4-methylpyrazole (4MP, Fomepizole) protects against APAP-induced liver injury by inhibiting reactive metabolite formation through Cyp2E1, and analysis of data from APAP overdose patients indicated that kidney dysfunction strongly correlated with severe liver injury.	Fomepizole	37-40	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	149-155
33157119-2	2020	We have shown that 4-methylpyrazole (4MP, Fomepizole) protects against APAP-induced liver injury by inhibiting reactive metabolite formation through Cyp2E1, and analysis of data from APAP overdose patients indicated that kidney dysfunction strongly correlated with severe liver injury.	Fomepizole	42-52	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	149-155
33157119-3	2020	Since Cyp2E1 is also expressed in the kidney, this study explored protection by 4MP against APAP-induced nephrotoxicity.	Fomepizole	80-83	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	6-12
33157119-9	2020	In conclusion, since reactive metabolite formation seems to be common in both liver and kidney, 4MP mediated inhibition of Cyp2E1 protects against APAP-induced nephrotoxicity.	Fomepizole	96-99	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	123-129
32762579-18	2020	Fomepizole: There is good animal evidence that fomepizole blocks CYP 2E1 with the potential to inhibit the toxic metabolism of paracetamol.	Fomepizole	0-10	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	65-72
33425517-6	2020	The treatment of ethylene glycol poisoning consists of supportive care, sodium bicarbonate, and the use of an antidote (ethanol or fomepizole) which inhibits alcohol dehydrogenase and thereby prevents the formation of toxic metabolites.	Fomepizole	131-141	aldo-keto reductase family 1 member A1	Homo sapiens	158-179
32762579-18	2020	Fomepizole: There is good animal evidence that fomepizole blocks CYP 2E1 with the potential to inhibit the toxic metabolism of paracetamol.	Fomepizole	47-57	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	65-72
32762579-26	2020	Although cimetidine and fomepizole inhibit CYP 2E1 in animals, there is insufficient evidence to recommend their use either as a primary treatment or adjunct therapy in paracetamol poisoning.	Fomepizole	24-34	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	43-50
30903181-0	2019	Delayed Treatment With 4-Methylpyrazole Protects Against Acetaminophen Hepatotoxicity in Mice by Inhibition of c-Jun n-Terminal Kinase.	Fomepizole	23-39	jun proto-oncogene	Mus musculus	111-116
32572070-2	2020	Here, we investigated whether ethanol consumption before pregnancy affects maternal or fetal health and whether pharmacological inhibition of CYP2E1, a major ethanol oxidation enzyme, by 4-methylpyrazole (4-MP) has therapeutic effects.	Fomepizole	187-203	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	142-148
32572070-2	2020	Here, we investigated whether ethanol consumption before pregnancy affects maternal or fetal health and whether pharmacological inhibition of CYP2E1, a major ethanol oxidation enzyme, by 4-methylpyrazole (4-MP) has therapeutic effects.	Fomepizole	205-209	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	142-148
32572070-5	2020	However, treatment with 4-MP, a CYP2E1 inhibitor, markedly ameliorated the reduction in insulin action and glucose disposal responsiveness in the livers of ethanol-fed mice.	Fomepizole	24-28	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	32-38
30903181-3	2019	4-Methylpyrazole (4MP) is an antidote for methanol and ethylene glycol poisoning, and we have recently shown that cotreatment of 4MP with APAP effectively prevents toxicity by inhibiting Cyp2E1.	Fomepizole	0-16	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	187-193
30903181-3	2019	4-Methylpyrazole (4MP) is an antidote for methanol and ethylene glycol poisoning, and we have recently shown that cotreatment of 4MP with APAP effectively prevents toxicity by inhibiting Cyp2E1.	Fomepizole	18-21	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	187-193
30903181-3	2019	4-Methylpyrazole (4MP) is an antidote for methanol and ethylene glycol poisoning, and we have recently shown that cotreatment of 4MP with APAP effectively prevents toxicity by inhibiting Cyp2E1.	Fomepizole	129-132	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	187-193
30903181-7	2019	4MP also prevented JNK activation in other liver injury models.	Fomepizole	0-3	mitogen-activated protein kinase 8	Mus musculus	19-22
30903181-9	2019	These data suggest that treatment with 4MP after the metabolism phase effectively prevents APAP-induced liver injury in the clinically relevant mouse model in vivo mainly through the inhibition of JNK activation.	Fomepizole	39-42	mitogen-activated protein kinase 8	Mus musculus	197-200
29739258-6	2018	In addition, 4MP largely prevented APAP-induced activation of c-Jun N-terminal kinase (JNK), mitochondrial translocation of phospho-JNK and Bax, and the release of mitochondrial intermembrane proteins.	Fomepizole	13-16	mitogen-activated protein kinase 8	Homo sapiens	62-85
31214899-1	2019	Fomepizole is used as an antidote to treat methanol poisoning due to its selectivity towards alcohol dehydrogenase.	Fomepizole	0-10	aldo-keto reductase family 1 member A1	Homo sapiens	93-114
29739258-6	2018	In addition, 4MP largely prevented APAP-induced activation of c-Jun N-terminal kinase (JNK), mitochondrial translocation of phospho-JNK and Bax, and the release of mitochondrial intermembrane proteins.	Fomepizole	13-16	mitogen-activated protein kinase 8	Homo sapiens	87-90
29739258-6	2018	In addition, 4MP largely prevented APAP-induced activation of c-Jun N-terminal kinase (JNK), mitochondrial translocation of phospho-JNK and Bax, and the release of mitochondrial intermembrane proteins.	Fomepizole	13-16	mitogen-activated protein kinase 8	Homo sapiens	132-135
29739258-6	2018	In addition, 4MP largely prevented APAP-induced activation of c-Jun N-terminal kinase (JNK), mitochondrial translocation of phospho-JNK and Bax, and the release of mitochondrial intermembrane proteins.	Fomepizole	13-16	BCL2 associated X, apoptosis regulator	Homo sapiens	140-143
27186430-6	2016	Alcohol dehydrogenase-mediated acetaldehyde production was implicated in ethanol-induced cell injury in Aldh2 deficient cells as ethanol-induced oxidative stress and cell death was partially inhibited by 4-methylpyrazole.	Fomepizole	204-220	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	0-21
28638383-8	2017	Alcohol induced GR nuclear translocation, which was enhanced by the alcohol dehydrogenase inhibitor fomepizole, suggesting that it was alcohol, not its metabolites, that engendered the effect.	Fomepizole	100-110	nuclear receptor subfamily 3 group C member 1	Homo sapiens	16-18
28300663-7	2017	During an in vitro mechanistic investigation, we found that gamma-H2AX generation by 1,2-DCP was clearly attenuated in the presence of disulfiram and 4-methylpyrazole, a specific cytochrome P450 2E1 (CYP2E1) inhibitor.	Fomepizole	150-166	H2A.X variant histone	Homo sapiens	60-70
28300663-7	2017	During an in vitro mechanistic investigation, we found that gamma-H2AX generation by 1,2-DCP was clearly attenuated in the presence of disulfiram and 4-methylpyrazole, a specific cytochrome P450 2E1 (CYP2E1) inhibitor.	Fomepizole	150-166	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	179-198
28300663-7	2017	During an in vitro mechanistic investigation, we found that gamma-H2AX generation by 1,2-DCP was clearly attenuated in the presence of disulfiram and 4-methylpyrazole, a specific cytochrome P450 2E1 (CYP2E1) inhibitor.	Fomepizole	150-166	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	200-206
27022678-5	2016	Coinjection of the ADH inhibitor, 4-methylpyrazole, with equine chorionic gonadotropin significantly decreases the number and developmental competence of oocytes ovulated in response to human chorionic gonadotropin/LH as compared with controls.	Fomepizole	34-50	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	19-22
27186430-6	2016	Alcohol dehydrogenase-mediated acetaldehyde production was implicated in ethanol-induced cell injury in Aldh2 deficient cells as ethanol-induced oxidative stress and cell death was partially inhibited by 4-methylpyrazole.	Fomepizole	204-220	aldehyde dehydrogenase 2, mitochondrial	Mus musculus	104-109
27455577-2	2016	Methanol antidote 4-methylpyrazole (non-competitive inhibitor of alcohol dehydrogenase) administered upon acute intoxication with methanol at a dose of 1.0 DL50 partially reduces the intoxication-induced suppression of humoral and cellular immune response, activity of T-helper cells, and production of IL-4 and restores blood levels of TNF, IL-1b, IFN-gamma, IL-4, IL-2, IL-6 to the control values.	Fomepizole	18-34	aldo-keto reductase family 1 member A1	Rattus norvegicus	65-86
26551875-5	2016	Although ethanol can be effective in these poisonings, there are substantial practical problems with its use and so fomepizole, a potent competitive inhibitor of alcohol dehydrogenase, was developed for a hopefully better treatment for metabolically-toxic alcohol poisonings.	Fomepizole	116-126	aldo-keto reductase family 1 member A1	Homo sapiens	162-183
26775039-0	2016	Ethanol and 4-methylpyrazole increase DNA adduct formation of furfuryl alcohol in FVB/N wild-type mice and in mice expressing human sulfotransferases 1A1/1A2.	Fomepizole	12-28	sulfotransferase family 1A member 1	Homo sapiens	132-157
26915245-6	2016	Fomepizole is the antidote for methanol and ethyleneglycol, blocking alcohol dehydrogenase.	Fomepizole	0-10	aldo-keto reductase family 1 member A1	Homo sapiens	69-90
27455577-2	2016	Methanol antidote 4-methylpyrazole (non-competitive inhibitor of alcohol dehydrogenase) administered upon acute intoxication with methanol at a dose of 1.0 DL50 partially reduces the intoxication-induced suppression of humoral and cellular immune response, activity of T-helper cells, and production of IL-4 and restores blood levels of TNF, IL-1b, IFN-gamma, IL-4, IL-2, IL-6 to the control values.	Fomepizole	18-34	interleukin 4	Rattus norvegicus	303-307
27455577-2	2016	Methanol antidote 4-methylpyrazole (non-competitive inhibitor of alcohol dehydrogenase) administered upon acute intoxication with methanol at a dose of 1.0 DL50 partially reduces the intoxication-induced suppression of humoral and cellular immune response, activity of T-helper cells, and production of IL-4 and restores blood levels of TNF, IL-1b, IFN-gamma, IL-4, IL-2, IL-6 to the control values.	Fomepizole	18-34	tumor necrosis factor	Rattus norvegicus	337-340
27455577-2	2016	Methanol antidote 4-methylpyrazole (non-competitive inhibitor of alcohol dehydrogenase) administered upon acute intoxication with methanol at a dose of 1.0 DL50 partially reduces the intoxication-induced suppression of humoral and cellular immune response, activity of T-helper cells, and production of IL-4 and restores blood levels of TNF, IL-1b, IFN-gamma, IL-4, IL-2, IL-6 to the control values.	Fomepizole	18-34	interleukin 1 beta	Rattus norvegicus	342-347
27455577-2	2016	Methanol antidote 4-methylpyrazole (non-competitive inhibitor of alcohol dehydrogenase) administered upon acute intoxication with methanol at a dose of 1.0 DL50 partially reduces the intoxication-induced suppression of humoral and cellular immune response, activity of T-helper cells, and production of IL-4 and restores blood levels of TNF, IL-1b, IFN-gamma, IL-4, IL-2, IL-6 to the control values.	Fomepizole	18-34	interferon gamma	Rattus norvegicus	349-358
27455577-2	2016	Methanol antidote 4-methylpyrazole (non-competitive inhibitor of alcohol dehydrogenase) administered upon acute intoxication with methanol at a dose of 1.0 DL50 partially reduces the intoxication-induced suppression of humoral and cellular immune response, activity of T-helper cells, and production of IL-4 and restores blood levels of TNF, IL-1b, IFN-gamma, IL-4, IL-2, IL-6 to the control values.	Fomepizole	18-34	interleukin 4	Rattus norvegicus	360-364
27455577-2	2016	Methanol antidote 4-methylpyrazole (non-competitive inhibitor of alcohol dehydrogenase) administered upon acute intoxication with methanol at a dose of 1.0 DL50 partially reduces the intoxication-induced suppression of humoral and cellular immune response, activity of T-helper cells, and production of IL-4 and restores blood levels of TNF, IL-1b, IFN-gamma, IL-4, IL-2, IL-6 to the control values.	Fomepizole	18-34	interleukin 2	Rattus norvegicus	366-370
27455577-2	2016	Methanol antidote 4-methylpyrazole (non-competitive inhibitor of alcohol dehydrogenase) administered upon acute intoxication with methanol at a dose of 1.0 DL50 partially reduces the intoxication-induced suppression of humoral and cellular immune response, activity of T-helper cells, and production of IL-4 and restores blood levels of TNF, IL-1b, IFN-gamma, IL-4, IL-2, IL-6 to the control values.	Fomepizole	18-34	interleukin 6	Rattus norvegicus	372-376
25817777-6	2015	The goal of this study was to compare withdrawal-associated behaviors in mice chronically treated with a liquid ethanol diet vs. mice treated with a short-term ethanol treatment that consisted of daily ethanol injections containing the alcohol dehydrogenase inhibitor, 4-methylpyrazole.	Fomepizole	269-285	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	236-257
25641189-5	2015	The rates of elimination of various alcohols were inhibited on average 73% (55% for 2-propanol to 90% for ethanol) by 1 mmol/kg of 4-methylpyrazole, a good inhibitor of ADH, indicating a major role for ADH in the metabolism of the alcohols.	Fomepizole	131-147	aldo-keto reductase family 1 member A1	Rattus norvegicus	169-172
25641189-5	2015	The rates of elimination of various alcohols were inhibited on average 73% (55% for 2-propanol to 90% for ethanol) by 1 mmol/kg of 4-methylpyrazole, a good inhibitor of ADH, indicating a major role for ADH in the metabolism of the alcohols.	Fomepizole	131-147	aldo-keto reductase family 1 member A1	Rattus norvegicus	202-205
26537191-6	2015	Blockade of retinol metabolism in mice given 4-methylpyrazole, an inhibitor of ADH, and ablated Raldh1 gene manifested increased migration of Tregs, eventually protected against Con A-mediated hepatitis by decreasing interferon-gamma in T cells.	Fomepizole	45-61	alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide	Mus musculus	79-82
26537191-6	2015	Blockade of retinol metabolism in mice given 4-methylpyrazole, an inhibitor of ADH, and ablated Raldh1 gene manifested increased migration of Tregs, eventually protected against Con A-mediated hepatitis by decreasing interferon-gamma in T cells.	Fomepizole	45-61	interferon gamma	Mus musculus	217-233
24668648-5	2014	In vitro treatment with 4-methylpyrazole (4-MP), a broad ADH inhibitor, or depletion of the ADH3 gene down-regulated collagen and transforming growth factor-beta1 (TGF-beta1) gene expression, but did not affect alpha-smooth muscle actin gene expression in cultured HSCs.	Fomepizole	24-40	transforming growth factor, beta 1	Mus musculus	130-162
24668648-5	2014	In vitro treatment with 4-methylpyrazole (4-MP), a broad ADH inhibitor, or depletion of the ADH3 gene down-regulated collagen and transforming growth factor-beta1 (TGF-beta1) gene expression, but did not affect alpha-smooth muscle actin gene expression in cultured HSCs.	Fomepizole	24-40	transforming growth factor, beta 1	Mus musculus	164-173
24668648-5	2014	In vitro treatment with 4-methylpyrazole (4-MP), a broad ADH inhibitor, or depletion of the ADH3 gene down-regulated collagen and transforming growth factor-beta1 (TGF-beta1) gene expression, but did not affect alpha-smooth muscle actin gene expression in cultured HSCs.	Fomepizole	42-46	transforming growth factor, beta 1	Mus musculus	130-162
24668648-5	2014	In vitro treatment with 4-methylpyrazole (4-MP), a broad ADH inhibitor, or depletion of the ADH3 gene down-regulated collagen and transforming growth factor-beta1 (TGF-beta1) gene expression, but did not affect alpha-smooth muscle actin gene expression in cultured HSCs.	Fomepizole	42-46	transforming growth factor, beta 1	Mus musculus	164-173
24287576-8	2014	Cytotoxicity was also significantly decreased by 4-methylpyrazole--a CYP2E1 inhibitor and by trichostatin--an inhibitor of histone deacetylases.	Fomepizole	49-65	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	69-75
24561005-5	2014	Compared to known inhibitors, inhibitory potency of 3,4-epoxy-1-butene is between 4-methylpyrazole (IC50 = 1.8 muM) and dimethylnitrosamine (IC50 = 230 muM).	Fomepizole	82-98	latexin	Homo sapiens	111-114
22228763-6	2012	Inhibition of alcohol dehydrogenase, cytochrome P450 2E1, and catalase with 4-methylpyrazole, trans-1,2-dichloroethylene, and 3-amino-1,2,3-triazole restored ethanol-suppressed ureagenic respiration by 46, 37, and 66%, respectively.	Fomepizole	76-92	aldo-keto reductase family 1 member A1	Rattus norvegicus	14-35
23352969-4	2013	MAIN METHODS: Chronic ethanol treated VL-17A cells over-expressing ADH and CYP2E1 were pretreated with the specific CYP2E1 inhibitor - diallyl sulfide or ADH inhibitor - pyrazole or ADH and CYP2E1 inhibitor - 4-methyl pyrazole.	Fomepizole	207-226	aldo-keto reductase family 1 member A1	Homo sapiens	67-70
23352969-6	2013	KEY FINDINGS: Inhibition of CYP2E1 with 10 muM diallyl sulfide or ADH with 2mM pyrazole or ADH and CYP2E1 with 5mM 4-methyl pyrazole led to decreased oxidative stress and toxicity in chronic ethanol (100 mM) treated VL-17A cells.	Fomepizole	115-132	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	28-34
23352969-6	2013	KEY FINDINGS: Inhibition of CYP2E1 with 10 muM diallyl sulfide or ADH with 2mM pyrazole or ADH and CYP2E1 with 5mM 4-methyl pyrazole led to decreased oxidative stress and toxicity in chronic ethanol (100 mM) treated VL-17A cells.	Fomepizole	115-132	aldo-keto reductase family 1 member A1	Homo sapiens	66-69
23352969-6	2013	KEY FINDINGS: Inhibition of CYP2E1 with 10 muM diallyl sulfide or ADH with 2mM pyrazole or ADH and CYP2E1 with 5mM 4-methyl pyrazole led to decreased oxidative stress and toxicity in chronic ethanol (100 mM) treated VL-17A cells.	Fomepizole	115-132	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	99-105
22807108-7	2012	We interrogated the allosteric mechanism using the CYP2E1-specific inhibitor and drug 4-methylpyrazole, which we have shown binds two CYP2E1 sites.	Fomepizole	86-102	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	134-140
22807108-8	2012	From the current studies, styrene was a positive allosteric effector on 4-methylpyrazole binding, based on a 10-fold increase in 4-methylpyrazole binding affinity from K(i) 0.51 to K(si) 0.043 muM.	Fomepizole	72-88	latexin	Homo sapiens	193-196
22807108-8	2012	From the current studies, styrene was a positive allosteric effector on 4-methylpyrazole binding, based on a 10-fold increase in 4-methylpyrazole binding affinity from K(i) 0.51 to K(si) 0.043 muM.	Fomepizole	129-145	latexin	Homo sapiens	193-196
22867114-6	2012	TASO toxicity was partially blocked by the CYP2E1 inhibitors diallyl sulfide and 4-methylpyrazole and was strongly inhibited by TA.	Fomepizole	81-97	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	43-49
23707663-5	2013	RESULTS: Inhibition of CYP2E1 with 10muM diallyl sulfide most effectively led to decreases in the oxidative stress and toxicity as compared with ADH inhibition with 2mM pyrazole or the combined inhibition of ADH and CYP2E1 with 5mM 4-methyl pyrazole.	Fomepizole	232-249	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	23-29
22554311-10	2012	DISCUSSION/CONCLUSION: The results suggest that fomepizole induces its own metabolism via cytochrome P-450, leading to enhanced fomepizole elimination and 4-CP excretion.	Fomepizole	48-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
22554311-10	2012	DISCUSSION/CONCLUSION: The results suggest that fomepizole induces its own metabolism via cytochrome P-450, leading to enhanced fomepizole elimination and 4-CP excretion.	Fomepizole	128-138	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-106
22228763-6	2012	Inhibition of alcohol dehydrogenase, cytochrome P450 2E1, and catalase with 4-methylpyrazole, trans-1,2-dichloroethylene, and 3-amino-1,2,3-triazole restored ethanol-suppressed ureagenic respiration by 46, 37, and 66%, respectively.	Fomepizole	76-92	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	37-56
20947616-6	2011	In animal and human liver S9, this metabolic pathway could be inhibited by 4-methylpyrazole, bis-p-nitrophenylphosphate (BNPP), or a brief heat treatment at 50 C. Based on these results, the overall metabolic pathway was believed to involve a two-step oxidation process: dehydrogenation of the secondary alcohol in liver cytosol followed by an FMO5-mediated Baeyer-Villiger oxidation in liver microsomes.	Fomepizole	75-91	flavin containing dimethylaniline monoxygenase 5	Homo sapiens	344-348
21679931-4	2011	Inhibition of alcohol-dehydrogenase, by preincubation of astrocytes in the presence of 4-methylpyrazole (1mM), abolished ethanol-induced inhibition of glutamate release in response to kainate.	Fomepizole	87-103	aldo-keto reductase family 1 member A1	Rattus norvegicus	14-35
21919919-3	2011	RESULTS: Incubation of HeLa-ADH1B cells with ethanol (20 mM) resulted in acetaldehyde accumulation in the media, which was prevented by co-incubation with 4-methyl pyrazole (4-MP), a specific inhibitor of ADH.	Fomepizole	155-172	alcohol dehydrogenase 1B (class I), beta polypeptide	Homo sapiens	28-33
21919919-3	2011	RESULTS: Incubation of HeLa-ADH1B cells with ethanol (20 mM) resulted in acetaldehyde accumulation in the media, which was prevented by co-incubation with 4-methyl pyrazole (4-MP), a specific inhibitor of ADH.	Fomepizole	174-178	alcohol dehydrogenase 1B (class I), beta polypeptide	Homo sapiens	28-33
19280452-4	2009	In the presence of 4MP, DAS, or the anti-oxidants vitamin D or catalase, there was a substantial decrease in the ability of ethanol to stimulate CCN2 mRNA expression and a concomitant decrease in CCN2-positive PSC.	Fomepizole	19-22	cellular communication network factor 2	Mus musculus	145-149
20724102-8	2010	The changes of the metabolic rates were qualitatively and in general quantitatively correlated to the results from simulations with the kinetic rate equations of ADH1 under a wide range of ethanol, in the presence of competitive inhibitor 4-methylpyrazole and of uncompetitive inhibitor isobutyramide.	Fomepizole	239-255	alcohol dehydrogenase 1C (class I), gamma polypeptide	Rattus norvegicus	162-166
20482279-9	2010	Similarly, lycopene and fomepizole decreased methanol-induced caspase-3 activity.	Fomepizole	24-34	caspase 3	Rattus norvegicus	62-71
20482279-12	2010	It was demonstrated for the first time that both lycopene and fomepizole prevent methanol-induced hepatic injury by reducing the increase of lipid oxidation and caspase-3 activation.	Fomepizole	62-72	caspase 3	Rattus norvegicus	161-170
21468195-2	2010	The current recommendation suggests that alcohol dehydrogenase inhibitor fomepizole is preferred to ethanol in treatment of methanol and ethylene glycol poisoning, but analysis of the enzyme kinetics indicates that ethanol is a better alternative.	Fomepizole	73-83	aldo-keto reductase family 1 member A1	Homo sapiens	41-62
18473182-8	2009	Iodotubericidin, which inhibits the conversion of AICAR to its activated form AICAR monophosphate, the antioxidants trolox and MnTMPyP, and 4-methylpyrazole, an inhibitor of CYP2E1, all can protect the E47 cells from AICAR-induced necrosis.	Fomepizole	140-156	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	174-180
19280452-4	2009	In the presence of 4MP, DAS, or the anti-oxidants vitamin D or catalase, there was a substantial decrease in the ability of ethanol to stimulate CCN2 mRNA expression and a concomitant decrease in CCN2-positive PSC.	Fomepizole	19-22	cellular communication network factor 2	Mus musculus	196-200
19004845-4	2009	Published data and data obtained from the drug"s manufacturer implies that the dose escalation after 48 hours is to compensate for fomepizole-induced increased body clearance resulting from autoinduction of the cytochrome P450 (CYP) drug metabolizing enzyme CYP2E1.	Fomepizole	131-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	211-226
19004845-4	2009	Published data and data obtained from the drug"s manufacturer implies that the dose escalation after 48 hours is to compensate for fomepizole-induced increased body clearance resulting from autoinduction of the cytochrome P450 (CYP) drug metabolizing enzyme CYP2E1.	Fomepizole	131-141	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	228-231
19004845-4	2009	Published data and data obtained from the drug"s manufacturer implies that the dose escalation after 48 hours is to compensate for fomepizole-induced increased body clearance resulting from autoinduction of the cytochrome P450 (CYP) drug metabolizing enzyme CYP2E1.	Fomepizole	131-141	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	258-264
18162528-7	2008	Inhibition of EtOH metabolism by 4-methylpyrazole inhibited the induction of CYP24A1 mRNA.	Fomepizole	33-49	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	77-84
18666320-8	2008	Additionally, 4-methylpyrazole prevented the ethanol-induced decreases in the IGF-I system, cell viability and p-JNK1/2 activity (at 180 min).	Fomepizole	14-30	insulin-like growth factor 1	Rattus norvegicus	78-83
18336631-11	2008	The nonmetabolizable alcohol tert-butanol increased REDD1 and the EtOH-induced increase in REDD1 was not prevented by pretreatment with the alcohol dehydrogenase inhibitor 4-methylpyrazole.	Fomepizole	172-188	DNA-damage-inducible transcript 4	Rattus norvegicus	91-96
18818195-5	2008	Structures of human CYP2E1 have been solved to 2.2 angstroms for an indazole complex and 2.6 angstroms for a 4-methylpyrazole complex.	Fomepizole	109-125	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	20-26
18289715-9	2008	Up-regulation of ANXA2 and p11 was inhibited by the alcohol dehydrogenase inhibitor 4-methylpyrazole.	Fomepizole	84-100	annexin A2	Homo sapiens	17-22
18289715-9	2008	Up-regulation of ANXA2 and p11 was inhibited by the alcohol dehydrogenase inhibitor 4-methylpyrazole.	Fomepizole	84-100	S100 calcium binding protein A10	Homo sapiens	27-30
17920042-3	2008	Inhibition of this pathway by ethanol (competing ADH substrate) or 4-methylpyrazole (ADH inhibitor) led to a dramatic increase in the 1-HMP-induced DNA adduct formation in rat tissues in the preceding study.	Fomepizole	67-83	inner membrane mitochondrial protein	Homo sapiens	136-139
18242813-5	2008	In a preceding study, cDNA-expressed human ADH2 efficiently oxidised 1-, 2- and 4-hydroxymethylpyrene; these reactions were inhibited in the presence of ethanol or 4-methylpyrazole.	Fomepizole	164-180	alcohol dehydrogenase 4 (class II), pi polypeptide	Homo sapiens	43-47
18003597-5	2008	Using the enzyme inhibitors 4-methylpyrazole and cyanamide and the metabolite acetaldehyde, we showed that PPARalpha and PPARbeta are differentially modulated by ethanol and acetaldehyde.	Fomepizole	28-44	peroxisome proliferator activated receptor alpha	Homo sapiens	107-116
18003597-5	2008	Using the enzyme inhibitors 4-methylpyrazole and cyanamide and the metabolite acetaldehyde, we showed that PPARalpha and PPARbeta are differentially modulated by ethanol and acetaldehyde.	Fomepizole	28-44	peroxisome proliferator activated receptor delta	Homo sapiens	121-129
18242813-8	2008	ADH1C and ADH4 activities towards hydroxymethylpyrenes were more strongly inhibited in the presence of ethanol and 4-methylpyrazole than those of ADH2.	Fomepizole	115-131	alcohol dehydrogenase 1C (class I), gamma polypeptide	Homo sapiens	0-5
18242813-8	2008	ADH1C and ADH4 activities towards hydroxymethylpyrenes were more strongly inhibited in the presence of ethanol and 4-methylpyrazole than those of ADH2.	Fomepizole	115-131	alcohol dehydrogenase 4 (class II), pi polypeptide	Homo sapiens	10-14
18242813-8	2008	ADH1C and ADH4 activities towards hydroxymethylpyrenes were more strongly inhibited in the presence of ethanol and 4-methylpyrazole than those of ADH2.	Fomepizole	115-131	alcohol dehydrogenase 4 (class II), pi polypeptide	Homo sapiens	146-150
18056994-8	2008	Similarly, 4MP and IND yielded type II binding spectra that reflected the association of either two 4MP or one IND molecule(s) to CYP2E1, respectively.	Fomepizole	11-14	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	130-136
17920042-10	2008	4-Methylpyrazole inhibited the oxidation of the HMP isomers as well as the reverse reaction.	Fomepizole	0-16	inner membrane mitochondrial protein	Homo sapiens	48-51
16971503-4	2006	Consistent with our in vivo findings, EtOH stimulated RANKL mRNA expression in cultured primary osteoblasts, and this expression was blocked by 4-methylpyrazole.	Fomepizole	144-160	TNF superfamily member 11	Rattus norvegicus	54-59
17870485-2	2007	Recent trials have demonstrated that fomepizole effectively blocks alcohol dehydrogenase (ADH) in toxic alcohol overdoses, and may eliminate the need for emergent hemodialysis and intensive care unit admission.	Fomepizole	37-47	aldo-keto reductase family 1 member A1	Homo sapiens	67-88
17870485-2	2007	Recent trials have demonstrated that fomepizole effectively blocks alcohol dehydrogenase (ADH) in toxic alcohol overdoses, and may eliminate the need for emergent hemodialysis and intensive care unit admission.	Fomepizole	37-47	aldo-keto reductase family 1 member A1	Homo sapiens	90-93
17870485-9	2007	Fomepizole was used for ADH blockade in 12/20 cases; ETOH infusions in 15/20 cases (combined ETOH and fomepizole use in 7/20).	Fomepizole	0-10	aldo-keto reductase family 1 member A1	Homo sapiens	24-27
17365107-4	2007	Treatment with 4-methylpyrazole blocked the IGF-I and IGFBP-1 secretion and p42/44 MAPK activity.	Fomepizole	15-31	insulin-like growth factor 1	Rattus norvegicus	44-49
17365107-4	2007	Treatment with 4-methylpyrazole blocked the IGF-I and IGFBP-1 secretion and p42/44 MAPK activity.	Fomepizole	15-31	insulin-like growth factor binding protein 1	Rattus norvegicus	54-61
16337880-7	2006	Serum withdrawal-induced E47 cell death could be rescued by antioxidants, the mitochondrial permeability transition inhibitor cyclosporine A, z-DEVD-fmk, and a CYP2E1 inhibitor 4-methylpyrazole.	Fomepizole	177-193	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	160-166
16814747-5	2006	Metabolite peak areas were substantially and significantly reduced by the CYP1A2 inhibitor furafylline and to a lesser extent by the CYP2E1 inhibitor 4-methylpyrazole.	Fomepizole	150-166	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	133-139
16501006-4	2006	Incubation of hepatocytes with 4-methylpyrazole resulted in a selective inhibition of CYP2E1 activity as determined by p-nitrophenol hydroxylase activity and an associated significant decrease in the production of the 3MI metabolites 3-hydroxy-3-methyloxindole and 3-methyloxindole.	Fomepizole	31-47	cytochrome P450 family 2 subfamily E member 1	Sus scrofa	86-92
16737972-5	2006	4-Methylpyrazole, a specific inhibitor of the alcohol-metabolizing enzymes, abolished the effects of ethanol on hepcidin.	Fomepizole	0-16	hepcidin antimicrobial peptide	Homo sapiens	112-120
16540368-6	2006	The changes in LPO, cytosolic GST activity, GSH levels and SAMe/SAH ratio in ethanol exposed hepatocytes were completely or partially reversed by either Vitamin E or 4-methylpyrazole, an alcohol dehydrogenase (ADH) inhibitor.	Fomepizole	166-182	hematopoietic prostaglandin D synthase	Mus musculus	30-33
15231826-13	2004	4-Methyl pyrazole, a classical competitive inhibitor of class I ADH, failed to inhibit ADH8A.	Fomepizole	0-17	alcohol dehydrogenase 1C (class I), gamma polypeptide	Rattus norvegicus	64-67
16035197-2	2005	Fomepizole (4-methylpyrazole) is a potent competitive inhibitor of alcohol dehydrogenase and is used as an antidote to treat methanol poisonings.	Fomepizole	0-10	aldo-keto reductase family 1 member A1	Homo sapiens	67-88
16035197-2	2005	Fomepizole (4-methylpyrazole) is a potent competitive inhibitor of alcohol dehydrogenase and is used as an antidote to treat methanol poisonings.	Fomepizole	12-28	aldo-keto reductase family 1 member A1	Homo sapiens	67-88
16208625-6	2005	The aim of the study was to evaluate the effect of alcohol dehydrogenase (ADH) inhibitors and substrates: cimetidine, EDTA, 4-methylpyrazole (4-MP), Ukrain and ethanol on LDH activity.	Fomepizole	142-146	aldo-keto reductase family 1 member A1	Homo sapiens	74-77
15653713-8	2005	The ethanol-induced fibronectin response was dependent on ethanol metabolism since 4-methylpyrazole, an inhibitor of alcohol dehydrogenase, abolished the effect and acetaldehyde induced it.	Fomepizole	83-99	fibronectin 1	Mus musculus	20-31
15578220-6	2005	We report on the use of fomepizole (4-methylpyrazole),a new and potent inhibitor of alcohol dehydrogenase, in a 3-year-old boy after the intake of a toxic amount of methanol.	Fomepizole	24-34	aldo-keto reductase family 1 member A1	Homo sapiens	84-105
15578220-6	2005	We report on the use of fomepizole (4-methylpyrazole),a new and potent inhibitor of alcohol dehydrogenase, in a 3-year-old boy after the intake of a toxic amount of methanol.	Fomepizole	36-52	aldo-keto reductase family 1 member A1	Homo sapiens	84-105
15289186-1	2004	OBJECTIVES: 4-Methylpyrazole (4-MP), an alcohol dehydrogenase (ADH) antagonist, is used for the treatment of ethylene glycol and methanol ingestions.	Fomepizole	12-28	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	40-61
15289186-1	2004	OBJECTIVES: 4-Methylpyrazole (4-MP), an alcohol dehydrogenase (ADH) antagonist, is used for the treatment of ethylene glycol and methanol ingestions.	Fomepizole	12-28	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	63-66
15289186-12	2004	CONCLUSIONS: Pretreatment with 4-MP significantly prolonged ethanol neurobehavioral toxicity in CD-1 mice, presumably by inhibiting its metabolism by ADH.	Fomepizole	31-35	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	150-153
15289186-1	2004	OBJECTIVES: 4-Methylpyrazole (4-MP), an alcohol dehydrogenase (ADH) antagonist, is used for the treatment of ethylene glycol and methanol ingestions.	Fomepizole	30-34	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	40-61
15289186-1	2004	OBJECTIVES: 4-Methylpyrazole (4-MP), an alcohol dehydrogenase (ADH) antagonist, is used for the treatment of ethylene glycol and methanol ingestions.	Fomepizole	30-34	aldo-keto reductase family 1, member A1 (aldehyde reductase)	Mus musculus	63-66
15242817-5	2004	CYP2E1 inhibitor-4-methylpyrazole decreased drug cytotoxicity in transduced cells and normalized elevated Ca2+ levels.	Fomepizole	17-33	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	0-6
14695664-7	2004	The CYP2E1 inhibitor, 4-methylpyrazole, could suppress increased prooxidant production in E47 cells.	Fomepizole	22-38	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	4-10
15135311-9	2004	The ethanol-induced changes occurring in this cell line were negated by addition of the ADH inhibitor, 4-methylpyrazole (4-MP), indicating the effects were due to ethanol metabolism.	Fomepizole	103-119	aldo-keto reductase family 1 member A1	Homo sapiens	88-91
15135311-9	2004	The ethanol-induced changes occurring in this cell line were negated by addition of the ADH inhibitor, 4-methylpyrazole (4-MP), indicating the effects were due to ethanol metabolism.	Fomepizole	121-125	aldo-keto reductase family 1 member A1	Homo sapiens	88-91
14973432-8	2004	In addition, a second group of rats was pretreated with the alcohol-dehydrogenase inhibitor 4-methyl-pyrazole (90 mg/kg) intraperitoneally (i.p.	Fomepizole	92-109	aldo-keto reductase family 1 member A1	Rattus norvegicus	60-81